Actuate Therapeutics, Inc. (ACTU): Total Assets
$14.04M
As of 2025-12-31
$5.20M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.04M | +50.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $9.32M | +211.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $3.00M | n/a | 2025-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $14.04M | +50.6% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $14.04M | -6.7% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $13.97M | -22.6% |
| Biovie Inc. (BIVI) | 2026-06-30 | $14.25M | -33.9% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $13.81M | -18.6% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $13.59M | -31.3% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $13.53M | +254.8% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $14.98M | -41.2% |
| Cingulate Inc. (CING) | 2025-12-31 | $15.07M | +1.4% |
Compare ACTU, XCUR, CYDY, BIVI side by side · Screen every company in Pharmaceutical Preparations ↗